Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

PDE11A Inhibitors

Phosphodiesterase 11A (PDE11A) is an enzyme belonging to the phosphodiesterase (PDE) family, which plays a crucial role in cellular signaling by hydrolyzing cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). These cyclic nucleotides act as second messengers in various signaling pathways that regulate physiological processes including cell proliferation, differentiation, and apoptosis. PDE11A, in particular, is distinguished by its ability to hydrolyze both cAMP and cGMP, positioning it as a key regulator of the intracellular levels of these molecules. Through its enzymatic activity, PDE11A influences the amplitude and duration of cyclic nucleotide signaling, thereby modulating the cellular responses to hormonal stimuli, neurotransmitters, and other extracellular signals. The specific expression of PDE11A in certain tissues, such as testis, prostate, and brain, suggests it plays significant roles in the physiological functions pertinent to these tissues, including reproductive physiology and neural signaling. The inhibition of PDE11A has emerged as an area of interest due to its implications in modulating the cAMP/cGMP-mediated signaling pathways. Inhibition of PDE11A leads to increased levels of cAMP and cGMP within the cell, enhancing the signaling pathways that are regulated by these cyclic nucleotides. The mechanisms of inhibition typically involve small molecules that bind to the catalytic domain of PDE11A, obstructing its ability to hydrolyze cyclic nucleotides. This results in prolonged activation of downstream signaling cascades, which can have various physiological effects depending on the cellular context and the specific balance of cyclic nucleotide signaling in the tissue. Inhibitors of PDE11A could, therefore, modulate processes like smooth muscle relaxation, neuroplasticity, and other functions regulated by cAMP and cGMP signaling. The precise understanding of PDE11A inhibition mechanisms not only contributes to the fundamental knowledge of cellular signaling regulation but also highlights the nuanced control of physiological processes through modulation of cyclic nucleotide levels.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

BC 11-38

686770-80-9sc-364350
sc-364350A
10 mg
50 mg
$228.00
$680.00
(0)

BC 11-38 acts as a selective phosphodiesterase 11A (PDE11A) inhibitor, characterized by its unique structural motifs that enable robust hydrogen bonding and hydrophobic interactions within the enzyme's active site. This compound exhibits distinct reaction kinetics, leading to a pronounced alteration in the enzyme's catalytic efficiency. Its molecular architecture promotes specific allosteric effects, influencing substrate affinity and modulating downstream signaling cascades effectively.

Tadalafil

171596-29-5sc-208412
50 mg
$180.00
13
(2)

Tadalafil is a PDE11A inhibitor which acts by inhibiting the degradation of cyclic guanosine monophosphate (cGMP), leading to an increase in cGMP concentrations, thus promoting muscle relaxation and increased blood flow in the corpus cavernosum.

YM 254890

568580-02-9sc-507356
1 mg
$510.00
(0)

YM-254890 exhibits inhibitory action against PDE11A by restricting the hydrolyzation of cGMP, leading to elevated cGMP levels which assist in vasodilation and muscle relaxation.